Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Aparicio-Bautista DI et al. | 2022 | intact cell/cell culture, SH-SY5Y (human neuroblastoma cell line) | magnetic field, 50/60 Hz, low frequency | - |
Nieminen V et al. | 2024 | intact cell/cell culture, SH-SY5Y (human neuroblastoma cell line) | magnetic field, 50/60 Hz, co-exposure, also other exposures without EMF | - |
Guo H et al. | 2004 | intact cell/cell culture, SNU cells (human gastric adenocarcinoma cell line) | magnetic field, 50/60 Hz | 97 mT |
Schimmelpfeng J et al. | 1997 | intact cell/cell culture, SV40-swiss-3T3 cells (mouse fibroblast cell line) and HL-60 cells (human acute myeloid leukaemia cell line) | magnetic field, 50/60 Hz | 2 mT |
Akbarnejad Z et al. | 2017 | intact cell/cell culture, U87 (human glioblastoma cell line) | magnetic field, signals/pulses, 50/60 Hz | 5–10 mT |
Kaszuba-Zwoinska J et al. | 2010 | intact cell/cell culture, U937 (human leukemic monocyte cell line) | magnetic field, signals/pulses, 50/60 Hz, co-exposure | 45 mT |
Tofani S et al. | 2001 | intact cell/cell culture, WiDr (colon adenocarcinoma cells), MCF-7 (breast adenocarcinoma cells), MRC-5 (embryonal lung cells), animal, mouse/CD-1 nu-nu (nude), whole body | magnetic field, static magnetic field, low frequency, 50/60 Hz, DC | 300 µT–2.5 mT |
Koh EK et al. | 2008 | intact cell/cell culture, different human prostate carcinoma cell lines (DU145, LNCaP, PC3) | magnetic field, 50/60 Hz, power transmission line | 0.2–2.5 mT |
Qiu L et al. | 2016 | intact cell/cell culture, human amniotic (FL) cells | magnetic field, 50/60 Hz | 0.4 mT |
Feng B et al. | 2016 | intact cell/cell culture, human amniotic cells | magnetic field, 50/60 Hz | 0.2–2 mT |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.